Immuneering Corp (NASDAQ: IMRX) kicked off on Monday, up 8.98% from the previous trading day, before settling in for the closing price of $6.35. Over the past 52 weeks, IMRX has traded in a range of $1.10-$10.08.
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -46.45%. While this was happening, its average annual earnings per share was recorded 30.31%. With a float of $44.78 million, this company’s outstanding shares have now reached $63.48 million.
Immuneering Corp (IMRX) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Immuneering Corp is 26.02%, while institutional ownership is 44.67%. The most recent insider transaction that took place on Oct 03 ’25, was worth 50,025. In this transaction Director of this company bought 7,500 shares at a rate of $6.67, taking the stock ownership to the 156,766 shares. Before that another transaction happened on Oct 01 ’25, when Company’s Chief Accounting Officer bought 300 for $6.39, making the entire transaction worth $1,917. This insider now owns 27,533 shares in total.
Immuneering Corp (IMRX) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -0.58 earnings per share (EPS), lower than consensus estimate (set at -0.44) by -0.13. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.35 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 30.31% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 8.51% during the next five years compared to -46.45% drop over the previous five years of trading.
Immuneering Corp (NASDAQ: IMRX) Trading Performance Indicators
Take a look at Immuneering Corp’s (IMRX) current performance indicators. Last quarter, stock had a quick ratio of 24.00.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.78, a number that is poised to hit -0.31 in the next quarter and is forecasted to reach -1.60 in one year’s time.
Technical Analysis of Immuneering Corp (IMRX)
The latest stats from [Immuneering Corp, IMRX] show that its last 5-days average volume of 1.58 million was superior to 1.46 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 37.32%.
During the past 100 days, Immuneering Corp’s (IMRX) raw stochastic average was set at 55.99%, which indicates a significant decrease from 59.12% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.62 in the past 14 days, which was higher than the 0.57 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.88, while its 200-day Moving Average is $3.60. Now, the first resistance to watch is $7.22. This is followed by the second major resistance level at $7.51. The third major resistance level sits at $7.98. If the price goes on to break the first support level at $6.45, it is likely to go to the next support level at $5.98. Assuming the price breaks the second support level, the third support level stands at $5.69.
Immuneering Corp (NASDAQ: IMRX) Key Stats
The company with the Market Capitalisation of 446.82 million has total of 41,570K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -61,040 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -14,430 K.
